Lack of beneficial effect of a tachykinin receptor antagonist in experimental colitis

被引:26
作者
Wallace, JL
McCafferty, DM
Sharkey, KA
机构
[1] Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Intestinal Dis Res Unit, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Fac Med, Dept Physiol & Biophys, Intestinal Dis Res Unit, Calgary, AB T2N 4N1, Canada
基金
英国医学研究理事会;
关键词
inflammatory bowel disease; lidocaine; substance P; inflammation;
D O I
10.1016/S0167-0115(97)01064-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nerves within the wall of the intestine may contribute to inflammatory responses, such as those occurring in inflammatory bowel disease. Studies in an experimental model of colitis have demonstrated that neuromodulation, through chemical sympathectomy or administration of lidocaine, can markedly attenuate granulocyte infiltration and tissue injury. Given the many pro-inflammatory effects of substance P, we have evaluated the effects of a tachykinin receptor (NK-1) antagonist, RP 67580, in models of acute colitis in the rat and guinea pig. While administration of RP 67580 and a second NK-1 antagonist (CP-96,345-1) significantly reduced the infiltration of granulocytes into colonic tissue during the first 12 h after induction of colitis in the rat, repeated administration of RP 67580 over a three day period failed to significantly affect granulocyte recruitment or the severity of tissue injury. In contrast, lidocaine enemas were effective in reducing both indices of inflammation/injury. In the guinea pig, similar observations were made. These observations demonstrate that blockade of NK-1 receptors over a three day period failed to significantly modify the course of experimental colitis. It remains possible that the beneficial effects of lidocaine may be due, in part, to inhibition of substance P release, and that the contribution of substance P to inflammation in experimental colitis occurs through NK-1 receptor-independent mechanisms. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 41 条
[1]   NEUROGENIC INFLAMMATION IN AIRWAYS [J].
BARNES, PJ .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1991, 94 (1-4) :303-309
[2]   NONPEPTIDE ANTAGONISTS, CP-96,345 AND RP-67580, DISTINGUISH SPECIES VARIANTS IN TACHYKININ NK(1)-RECEPTORS [J].
BARR, AJ ;
WATSON, SP .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 108 (01) :223-227
[3]  
BERNSTEIN CN, 1993, AM J GASTROENTEROL, V88, P908
[4]   TOPICAL TREATMENT OF ULCERATIVE PROCTITIS WITH LIDOCAINE [J].
BJORCK, S ;
DAHLSTROM, A ;
AHLMAN, H .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 (09) :1061-1072
[5]   NITRIC-OXIDE SYNTHASE ACTIVITY IN ULCERATIVE-COLITIS AND CROHNS-DISEASE [J].
BOUGHTONSMITH, NK ;
EVANS, SM ;
HAWKEY, CJ ;
COLE, AT ;
BALSITIS, M ;
WHITTLE, BJR ;
MONCADA, S .
LANCET, 1993, 342 (8867) :338-340
[6]  
CALVO CF, 1992, J IMMUNOL, V148, P3498
[7]   RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST BLOCKS THE PROINFLAMMATORY ACTIVITY OF ENDOGENEOUS INTERLEUKIN-1 IN RABBIT IMMUNE COLITIS [J].
COMINELLI, F ;
NAST, CC ;
DUCHINI, A ;
LEE, M .
GASTROENTEROLOGY, 1992, 103 (01) :65-71
[8]  
DAVIS DR, 1955, SURG GYNECOL OBSTET, V101, P208
[9]   SUBSTANCE P-INDUCED CUTANEOUS PLASMA EXTRAVASATION IN RATS IS MEDIATED BY NK-1 TACHYKININ RECEPTORS [J].
DEVOR, M ;
PAPIRKRICHELI, D ;
NACHMIAS, E ;
ROSENTHAL, F ;
GILON, C ;
CHOREV, M ;
SELINGER, Z .
NEUROSCIENCE LETTERS, 1989, 103 (02) :203-208
[10]   OCTREOTIDE EFFECTIVELY DECREASES MUCOSAL DAMAGE IN EXPERIMENTAL COLITIS [J].
ELIAKIM, R ;
KARMELI, F ;
OKON, E ;
RACHMILEWITZ, D .
GUT, 1993, 34 (02) :264-269